![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
JNJ-64530440 (JNJ-0440), A Novel, Class N Capsid Assembly Modulator (CAM-N): Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Multiple Ascending Doses in Patients with Chronic Hepatitis B
|
|
|
AASLD 2019 Nov 8-11 Boston
Ed Gane1, Christian Schwabe2, Oliver Lenz3, Thierry Verbinnen3, Willem Talloen3, Thomas N. Kakuda4, Chris Westland4, Megha Patel4, Jeysen Yogaratnam4*, Leonard Dragone4and Pieter Van Remoortere5
1New Zealand Liver Transplant Unit, University of Auckland, Auckland, New Zealand; 2Auckland Clinical Studies, Auckland, New Zealand; 3Janssen Pharmaceutica NV, Beerse, Belgium; 4Janssen BioPharma Inc., South San Francisco, CA, USA; 5Janssen Pharmaceuticals, Titusville, NJ, USA; *J. Yogaratnam is no longer with Janssen Biopharma
![1119191](../images/111919/111919-1/1119191.gif)
![1119192](../images/111919/111919-1/1119192.gif)
![1119193](../images/111919/111919-1/1119193.gif)
![1119194](../images/111919/111919-1/1119194.gif)
![1119195](../images/111919/111919-1/1119195.gif)
![1119196](../images/111919/111919-1/1119196.gif)
![1119197](../images/111919/111919-1/1119197.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|